Proof Of Concept : Immunogenicity and Safety of hepB Injection in the Dermis Using VAX-ID

Summary

A proof of concept (POC) study will be conducted in 44 volunteers that have been fully vaccinated against hepatitis B in the past (at least 5 years ago) to assess the safety and immunogenicity of intradermal vaccination with hepatitis B surface vaccine antigen using a newly developed intradermal injection device VAX-ID, compared to intramuscular and intradermal (Mantoux technique) injection.

Timeline

Start

2016-03

Primary completion

2016-12

Completion

2016-12

Drugs

Indications